3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Adenocarcinoma of Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Mouth Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Barrett Esophagus
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Oropharyngeal Neoplasms
1
Laryngeal Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Esophageal Neoplasms
1
Carcinoma, Basal Cell
1
Adenocarcinoma, Follicular
1
Interventions
Carboplatin
19
Paclitaxel
18
Fluorouracil
16
Cisplatin
16
pembrolizumab
15
Radiotherapy
14
Oxaliplatin
12
Irinotecan
12
Capecitabine
12
Cyclophosphamide
10
Radiation
8
Leucovorin
8
Docetaxel
8
fludarabine
6
Taxes
6
Gemcitabine
6
Trastuzumab
5
fludarabine phosphate
4
aldesleukin
4
LY6K protein, human
4
Fluorodeoxyglucose F18
4
Erlotinib Hydrochloride
4
Bevacizumab
4
spartalizumab
3
Surgical Procedures, Operative
3
S 1 (combination)
3
Pemetrexed
3
Nivolumab
3
Drug Therapy
3
zimberelimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Esophageal Neoplasms
×
2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a
×
Clear all
NCT03757754
2018-11-29
HPPH
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 1
Unknown
30 enrolled